Literature DB >> 21971669

Case-matched comparison with standard versus reduced intensity conditioning regimen in chronic myeloid leukemia patients.

Pervin Topcuoglu1, Mutlu Arat, Muhit Ozcan, Onder Arslan, Osman Ilhan, Meral Beksac, Gunhan Gurman.   

Abstract

This retrospective case-matched study evaluated the efficacy of reduced intensity conditioning (RIC) regimen on early and late allogeneic transplant outcome in chronic myeloid leukemia (CML) patients. Twenty-eight patients conditioned with RIC regimen were matched to 56 patients who received a myeloablative conditioning (MAC) regimen. The main criteria for case matching among our CML allotransplant cohort were the Gratwohl scoring system. The median score was 2 (1-4) in each group. The pretransplant disease status was first chronic phase (CP1, n = 20), CP2 (n = 2), and advanced phase (n = 6) in RIC, and CP1 (n = 46), CP2 (n = 3), and advanced phase (n = 7) in MAC. The duration of neutropenia and thrombocytopenia was shorter in RIC than MAC. The grade and duration of mucositis were less in RIC. The need for total parenteral nutrition (21% vs. 77%, p < 0.0001) and febrile neutropenic episodes (50% vs. 95%, p < 0.0001) were observed less frequently in RIC compared with MAC-given patients. Acute or chronic graft versus host diseases (GvHD) were not affected by the intensity of conditioning regimen. The incidence of transplant-related mortality was higher in MAC (7% vs. 14%, p = 0.01). Although more relapse/progression was observed in the RIC group, the probability of 5- and 10-year leukemia-free- and overall survival were similar regardless of conditioning regimen intensity (p > 0.05). In early first CP, the pair of female donor-male recipient and the development of chronic GvHD prolonged both leukemia-free survival and overall survival in multivariate analysis. According to our single-center matched-pair analysis, the use of RIC regimens in patients with low-risk CML results with toxicities less, responses later, and relapses more frequent than the MAC regimens.

Entities:  

Mesh:

Year:  2011        PMID: 21971669     DOI: 10.1007/s00277-011-1349-2

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  7 in total

Review 1.  Optimization of nutrition support practices early after hematopoietic cell transplantation.

Authors:  Kerry K McMillen; Tara Coghlin-Dickson; Peter A Adintori
Journal:  Bone Marrow Transplant       Date:  2020-10-10       Impact factor: 5.483

Review 2.  The role of stem cell transplantation for chronic myelogenous leukemia in the 21st century.

Authors:  A John Barrett; Sawa Ito
Journal:  Blood       Date:  2015-04-07       Impact factor: 22.113

Review 3.  Management of Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia in the Accelerated or Blastic Phase.

Authors:  Uday Deotare; Dennis Dong Hwan Kim; Jeffrey H Lipton
Journal:  Drugs Aging       Date:  2016-05       Impact factor: 3.923

Review 4.  Pushing the envelope-nonmyeloablative and reduced intensity preparative regimens for allogeneic hematopoietic transplantation.

Authors:  S R Pingali; R E Champlin
Journal:  Bone Marrow Transplant       Date:  2015-05-18       Impact factor: 5.483

Review 5.  Allogeneic transplantation for CML in the TKI era: striking the right balance.

Authors:  Andrew J Innes; Dragana Milojkovic; Jane F Apperley
Journal:  Nat Rev Clin Oncol       Date:  2015-11-17       Impact factor: 66.675

6.  Comment on "Nutritional status of patients submitted to transplantation of allogeneic hematopoietic stem cells: a retrospective study".

Authors:  Erin M Schmidt; Kerry K McMillen
Journal:  Rev Bras Hematol Hemoter       Date:  2014-10-01

7.  Allogeneic Transplantation in Chronic Myeloid Leukemia and the Effect of Tyrosine Kinase Inhibitors on Survival: A Quasi-Experimental Study.

Authors:  Mehmet Özen; Celalettin Üstün; Bengi Öztürk; Pervin Topçuoğlu; Mutlu Arat; Mehmet Gündüz; Erden Atilla; Gülşen Bolat; Önder Arslan; Taner Demirer; Hamdi Akan; Osman İlhan; Meral Beksaç; Günhan Gürman; Muhit Özcan
Journal:  Turk J Haematol       Date:  2016-04-18       Impact factor: 1.831

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.